Elevation Point Wealth Partners LLC Purchases 44,964 Shares of Medtronic PLC $MDT

Elevation Point Wealth Partners LLC lifted its holdings in Medtronic PLC (NYSE:MDT) by 152.5% during the 1st quarter, Holdings Channel reports. The fund owned 74,439 shares of the medical technology company’s stock after acquiring an additional 44,964 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Medtronic were worth $6,485,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Curbstone Financial Management Corp increased its holdings in shares of Medtronic by 1.8% in the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock valued at $537,000 after purchasing an additional 100 shares during the period. New England Capital Financial Advisors LLC boosted its holdings in shares of Medtronic by 7.8% during the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock worth $135,000 after purchasing an additional 101 shares during the period. Ipsen Advisor Group LLC grew its position in Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after purchasing an additional 101 shares in the last quarter. Quadrant Capital Group LLC grew its position in Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after purchasing an additional 101 shares in the last quarter. Finally, Baker Tilly Wealth Management LLC increased its stake in Medtronic by 3.3% in the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock valued at $309,000 after buying an additional 102 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MDT shares. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. The Goldman Sachs Group dropped their price target on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Sanford C. Bernstein cut their price objective on Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. Rothschild & Co Redburn reduced their price objective on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Finally, UBS Group lowered their target price on Medtronic from $90.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Seventeen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.00.

Medtronic Stock Performance

MDT opened at $83.07 on Friday. The stock has a 50-day moving average of $79.04 and a 200-day moving average of $89.06. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The company has a market cap of $106.33 billion, a PE ratio of 22.27, a price-to-earnings-growth ratio of 2.23 and a beta of 0.56.

Medtronic (NYSE:MDT) last posted its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. The firm had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a $0.72 dividend. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.5%. Medtronic’s dividend payout ratio is presently 77.21%.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Investors continue to reward Medtronic’s stronger-than-expected fiscal Q4 results and improved fiscal 2027 outlook, which included solid revenue growth and guidance that supports a more constructive growth narrative for the stock.
• Positive Sentiment: Medtronic expanded its partnership with Retia Medical to distribute the Argos cardiac output monitor more broadly, supporting growth in high-acuity cardiovascular and critical-care markets and reinforcing the company’s expansion into higher-growth device categories. Article Title
• Positive Sentiment: Analyst sentiment remains favorable, with recent coverage showing a “Moderate Buy” tone and several firms maintaining bullish ratings, which may be helping support the share price. Article Title
• Neutral Sentiment: Articles discussing why MDT is up since its last earnings report suggest the move may be a continuation of post-earnings buying rather than a reaction to a fresh catalyst, indicating momentum more than a new surprise. Article Title
• Neutral Sentiment: Medtronic has begun notifying people affected by a cyberattack, but the company said there is no evidence the accessed data was posted online and no impact to patient safety or core operations has been identified so far. Article Title
• Negative Sentiment: The cybersecurity incident still introduces headline risk and potential reputational or legal concerns, even though Medtronic says the event has not affected operations.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).